Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on its optimism about the company’s prophylactic treatment for Hereditary Angioedema (HAE).
Why JMP Securities Increased Its Price Target
After evaluating other companies’ treatments for the rare disease of HAE, which causes extensive swelling, JMP raised its revenue estimate for Pharvaris’ prophylactic treatment, deucrictibant. The investment bank believes that deucrictibant will outsell KalVista Pharmaceuticals,(KALV) sebetralstat if both treatments for HAE are approved.
A scientist in a lab coat mixing the chemicals for the Liposomal Bcl-2 drug development.
Meanwhile, based on the data from Pharvaris’ Phase 2 trial, JMP expects the extended-release version of the company’s deucrictibant to obtain a meaningful share of the market for prophylactic treatments of HAE.
Finally, JMP increased its estimate of the addressable market for Pharvaris’ drug.
PHVS’ Expected Upcoming Data Timeline
Earlier this month, PHVS reported that it expects to report in the first quarter of 2026 the topline data from a Phase 3 trial of deucrictibant for the on-demand treatment of HAE. In the second half of 2026, the drug maker expects to report topline data from a pivotal Phase 3 study of deucrictibant for prophylaxis against HAE attacks.
The Recent Price Action of PHVS Stock
In the last month, PHVS has dropped 2%, while it has tumbled 25% in the last three months.
READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
This article is originally published at Insider Monkey.
